Mesotelioma pleural

  1. Villena Garrido, V. 1
  2. Hernández Voth, A. 1
  3. Corral Blanco, M. 1
  1. 1 Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, España Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2022

Titre de la publication: Patología respiratoria (V)

Serie: 13

Número: 67

Pages: 3953-3960

Type: Article

DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Pleural mesothelioma is the main malignant pleural tumor. Most cases are associated with inhalation of asbestos fibers. The most frequent manifestations are dyspnea and chest pain in patients in pleural effusion and/or nodular pleural thickening. The diagnosis is histological, distinguishing between three big subgroups: epithelioid, sarcomatoid, and biphasic. The most used staging is based on the TNM staging system and proposed by the International Association for the Study of Lung Cancer (IASLC). The principal prognostic factors, in addition to TNM stage, are the histological type, age, and the patient's overall condition. In select patients, surgery may be indicated as part of multimodal treatment. In order to determine which patients are candidates for surgery, in addition to the epithelial histological type, an adequate cardiopulmonary reserve, an extension study with a computed tomography scan of the chest and abdomen, magnetic resonance imaging, positron emission tomography, and an examination of the mediastinum with endobronchial ultrasound or mediastinoscopy should be taken into account. In patients who are not candidates for surgery, chemotherapy in a platinum/pemetrexed regimen and/or symptomatic treatment that includes pleurodesis and control of pain and dyspnea should be considered.

Références bibliographiques

  • López Abente G, García Gómez M, Menéndez Navarro A, Fernández Navarro P, Ramis R, García Pérez J. Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020. BMC Cancer. 2013;13:528.
  • Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers. 2021;13:4194.
  • Attanoos RL, Churg A, Galateau Salle F, Gibbs AR, Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018;142:753-60.
  • Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207-18.
  • Beasley MB, Francoise Galateau Salle F, Dacic S. Pleural mesothelioma classification update. Virchows Arch. 2021;478:59-72.
  • Rozitis E, Johnson B, Cheng YY, Lee K. The use of immunohistochemistry, fluorescence in situ hybridization, and emerging epigenetic markers in the diagnosis of malignant pleural mesothelioma (MPM): A review. Front Oncol. 2020;10:1742.
  • Mneimneh WS, Jiang Y, Harbhajanka A, Michael CW. Immunochemistry in the work-up of mesothelioma and its differential diagnosis and mimickers. Diagn Cytopathol. 2021;49:582-95.
  • Sinha S, Swift AJ, Kamil MA, Matthews S, Bull MJ, Fisher P. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol. 2020; 75:423-32.
  • Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev. 2021;30:210057.
  • Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The Sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010; 38: 874-9.
  • Hallifax RJ, Corcoran JP, Ahmed A, Nagendran M, Rostom H, Hassan N. Physician-based ultrasound-guided biopsy for diagnosing pleural disease. Chest. 2014;146:1001-6.
  • Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJ, Downer NJ. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65:Suppl2:ii54-ii60.
  • Amin MB, Edge SB, Greene FL, Schilsky RL, Byrd DR, Gaspar LE AJCC (American Joint Committee on Cancer) Cancer Sta- ging Manual. 8th ed. Chicago: Springer; 2017.
  • Schumann SO, Kocher G, Minervini F. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13:2510-23.
  • Remona J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020;147:83-90.
  • Finn RS, Brims FJ, Gandhi A, Olsen N, Musk AW, Maskell NA. Postmortem findings of malignant pleural mesothelioma: A two-center study of 318 patients. Chest. 2012;142:1267-73.
  • Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145-52.
  • Herndon JE, Green MR, Chahinian AP, van Meerbeeck J, Postmus PE, Giaccone G. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723-31.
  • Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis. J Thorac Oncol. 2016;11:573-82.
  • Opitz I, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953.
  • Nadal E, Bosch Barrera J, Cedrés S, Coves J, García Campelo R, Guirado M. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Trans Oncol. 2021;23:980-7.
  • Wolf AS, Flores RM. Updates in staging and management of malignant pleural mesothelioma. Surg Oncol Clin N Am. 2020;29:603-12.
  • Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev. 2021;30:200226.
  • Luna J, Bobo A, Cabrera Rodríguez JJ, Pagola M, Martín Martín M, González Ruiz MA. GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma. World J Clin Oncol. 2021;12:581-608.
  • Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res. 2020;9Suppl1:S100-19.
  • Sidhu C, Louw A, Lee YCG. Malignant pleural mesothelioma. Updates for respiratory physicians. Clin Chest Med. 2021;42:697-710.
  • Treasure T, Lang Lazdunski L, Waller D, BlissJM, Tan C, Entwisle J. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763-72.
  • Ripley RT. Extended pleurectomy and decortication for malignant pleural mesothelioma. Thorac Surg Clin. 2020;30:451-60.
  • Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S. Mesothelioma and radical surgery 2 (MARS 2): protocol for a multicentre randomized trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020;10:e038892.
  • Romei C, Fanni SC, Volpi F, Milazzo A, D’Amore CA, Colligiani L. New updates of the imaging role in diagnosis, staging, and response treatment of malignant pleural mesothelioma. Cancers. 2021;13:4377.
  • Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crinò L. Malignant pleural mesothelioma: State-of-the-Art on current therapies and promises for the future. Front Oncol. 2020;9:1519
La source de données: Dialnet